We conducted a case-study study on Osimertinib, the preferred regimen for first and subsequent line of therapy in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with or without brain metastases [3]. Here, EGFR is linked to non-small cell lung carcinoma.